GlucoTrack (NASDAQ:GCTK) Announces Quarterly Earnings Results

GlucoTrack (NASDAQ:GCTK) issued its earnings results on Friday. The company reported $0.76 earnings per share (EPS) for the quarter, FiscalAI reports.

GlucoTrack Price Performance

Shares of NASDAQ:GCTK traded up $0.00 during midday trading on Friday, hitting $0.37. The stock had a trading volume of 591,530 shares, compared to its average volume of 25,540,708. The company’s 50-day moving average price is $0.40 and its 200-day moving average price is $0.88. GlucoTrack has a fifty-two week low of $0.25 and a fifty-two week high of $14.14. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $2.84 million, a P/E ratio of -0.02 and a beta of 0.70.

Wall Street Analyst Weigh In

GCTK has been the topic of several research analyst reports. Wall Street Zen raised shares of GlucoTrack from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GlucoTrack in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Hedge Funds Weigh In On GlucoTrack

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its holdings in GlucoTrack by 102,125.0% during the 2nd quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock worth $25,000 after buying an additional 4,085 shares during the period. Boothbay Fund Management LLC bought a new position in shares of GlucoTrack during the fourth quarter worth about $52,000. Finally, Ikarian Capital LLC acquired a new position in shares of GlucoTrack in the fourth quarter worth approximately $177,000. Institutional investors and hedge funds own 10.92% of the company’s stock.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.